Loading...
•
Dec 31, 2025
Atea Q4 2025 Earnings Report
Atea Pharmaceuticals reported fourth quarter 2025 financial results, highlighting progress in its Phase 3 Hepatitis C program and the expansion of its antiviral pipeline into Hepatitis E.
Key Takeaways
Atea Pharmaceuticals ended Q4 2025 with $301.8 million in cash while advancing its global Phase 3 HCV program. The company completed enrollment for the C-BEYOND trial and expects topline results in 2026. Financials reflected increased R&D spending for clinical trials, offset by lower G&A costs and a one-time tax benefit.
Completed enrollment for the Phase 3 C-BEYOND HCV trial in North America with over 880 patients.
Expects topline results for C-BEYOND in mid-2026 and C-FORWARD by year-end 2026.
Expanded pipeline with AT-587 for Hepatitis E Virus (HEV), with clinical entry expected mid-2026.
Recorded a net loss of $44.9 million for Q4 2025, impacted by increased Phase 3 clinical trial expenses.
Forward Guidance
Atea is focused on clinical milestones for its HCV and HEV programs through 2026.
Positive Outlook
- Topline results from North American C-BEYOND (HCV) trial expected mid-2026.
- Topline results from C-FORWARD (HCV) trial anticipated year-end 2026.
- Clinical development for AT-587 (HEV) expected to begin mid-2026.
- BEM/RZR regimen shows high barrier to resistance and low drug-drug interaction risk.
- Potential first-in-class inhibitor profile for AT-587 in HEV.
Challenges Ahead
- Significant decrease in cash and investments compared to the prior year.
- Increased R&D costs due to late-stage Phase 3 clinical trials.
- No currently approved antiviral therapy for HEV, representing regulatory risk.
- Competition from existing approved treatments for HCV.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...